This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Detecting Abnormal Blood Clotting in Patients With Metastatic Cancer Undergoing Surgery

This study has been completed.
Information provided by:
National Cancer Institute (NCI) Identifier:
First received: November 11, 2004
Last updated: May 9, 2009
Last verified: June 2007

RATIONALE: A test that detects abnormal blood clotting in patients with cancer may help doctors plan cancer surgery.

PURPOSE: This laboratory study is looking at a new blood test to detect abnormal clotting in patients with metastatic cancer undergoing surgery.

Condition Intervention
Thromboembolism Unspecified Adult Solid Tumor, Protocol Specific Other: coagulation study Other: immunoenzyme technique Other: laboratory biomarker analysis Other: physiologic testing Procedure: study of high risk factors

Study Type: Observational
Official Title: Evaluation of a Novel Blood Test Hypercoagulability in Surgical Patients With Metastatic Carcinoma: A Pilot Study

Resource links provided by NLM:

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Incidence of hypercoagulability

Secondary Outcome Measures:
  • Comparison of the results of whole blood thrombin generation assay tests in patients who develop venous thromboembolism with those who do not

Estimated Enrollment: 60
Study Start Date: November 2004
Detailed Description:



  • Determine whether whole blood thrombin generation assay (WBTGA) detects hypercoagulability in patients with metastatic carcinoma compared with a healthy control group.
  • Determine whether results of the WBTGA will change as a result of major surgery performed on patients with metastatic carcinoma.
  • Establish a reference interval for the WBTGA using healthy controls.


  • Compare a battery of plasma components known to affect or reflect coagulant or fibrinolytic reactions in patients with metastatic carcinoma vs healthy controls.
  • Establish reference intervals for this battery of tests using healthy controls.
  • Determine how major surgery in cancer patients affects this battery of factors.
  • Identify changes in these factors that correlate with changes in the WBTGA.
  • Compare the results of WBTGA tests in patients who develop venous thromboembolism (VTE) with those who do not.

OUTLINE: This is a pilot study.

Blood samples of patients are collected on day -7 and day 1 after surgery.

Blood samples of healthy controls are collected once.

After collection, blood samples are analyzed for hypercoagulability by whole blood thrombin generation assay. Routine blood tests are performed, as are immunoenzyme techniques for antigenic tissue plasminogen activator and its inhibitor, thrombin-antithrombin complexes, tissue factor, factor VIIa, D-dimer, and glycocalicin.

PROJECTED ACCRUAL: A total of 30 patients and 30 healthy controls will be accrued for this study.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes


  • Patients meeting the following criteria:

    • Diagnosis of metastatic carcinoma
    • Must be enrolled in 1 of the following surgical protocols:

      • NCI-99-C-0123
      • NCI-00-C-0069
      • NCI-03-C-0085
      • NCI-03-C-0212
  • Healthy control participant* meeting the following criteria:

    • No anemia or thrombocytopenia
    • No history of venous thromboembolism (deep vein thrombosis, pulmonary emboli)
    • No history of coronary artery disease or stroke
    • No chronic inflammatory disease
    • No diabetes mellitus
    • Have not smoked tobacco within the past 6 months NOTE: * Selected on the basis of gender and age to match the patients as they are accrued


  • No symptomatic infections or other acute illness within the past 14 days


  • At least 3 days since prior drugs known to inhibit platelet function
  • At least 7 days since prior acetylsalicylic acid
  • No concurrent estrogen contraceptives or hormone replacement therapy
  • No concurrent anticoagulants
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00096590

United States, Maryland
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States, 20892
Sponsors and Collaborators
National Cancer Institute (NCI)
Principal Investigator: McDonald K. Horne, MD National Cancer Institute (NCI)
  More Information

Publications: Identifier: NCT00096590     History of Changes
Obsolete Identifiers: NCT00464360
Other Study ID Numbers: CDR0000440092
Study First Received: November 11, 2004
Last Updated: May 9, 2009

Keywords provided by National Cancer Institute (NCI):
unspecified adult solid tumor, protocol specific

Additional relevant MeSH terms:
Embolism and Thrombosis
Vascular Diseases
Cardiovascular Diseases processed this record on September 19, 2017